Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC 4.0Dermatology and Therapy

Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa

  • Amit Garg1
  • Joslyn Kirby2
  • Theresa Amoloja2
  • J. Morel Symons2
  • Joseph Cordaro2
  • Alex Silberzweig1
  • Andrew Strunk1
  1. 1Department of Dermatology, Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY 11042-1069 USA
  2. 2Incyte Corporation, Wilmington, DE USA
Read full textPDFDOICite

Abstract

Introduction: The risk of thromboembolism in patients with hidradenitis suppurativa (HS) has not been established. This study aimed to estimate the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) among adults with HS and demographic subgroups.

Methods: This retrospective cohort study was conducted between January 1, 2017, and December 31, 2024, using a health insurance claims database (Optum Clinformatics DataMart) in the US. Adults aged ≥ 18 years with an outpatient visit linked to a diagnosis of HS or any other diagnosis (controls) were eligible. Patients with prior diagnosis of either outcome or associated conditions were excluded. The primary outcomes evaluated were new-onset DVT and PE.

Results: Mean (SD) age was 43 (16) years for eligible patients with HS (n = 44,520) and 54 (19) years for control patients (n = 3,792,627). Incidence of DVT was 3.0 (95% CI 2.5–3.4) and 3.5 (95% CI 3.4–3.5) per 1000 person-years (PY) in patients with HS and controls, respectively. Incidence of PE was 2.4 (95% CI 2.0–2.8) and 2.2 (95% CI 2.2–2.3) per 1000 PY in patients with HS and controls, respectively. In demographics-adjusted analyses, standardized incidence ratios for DVT and PE were 1.42 (95% CI 1.23–1.65) and 1.78 (95% CI 1.50–2.10), respectively. Comorbidity-adjusted hazard ratios for DVT and PE were 1.12 (95% CI 0.97–1.31) and 1.35 (95% CI 1.14–1.60), respectively. Incidence of DVT was higher in patients with HS by a factor of 1.5–2.9 for age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.5 to 8.8 per 1000 PY. Incidence of PE was higher in patients with HS by a factor of 1.5–3.2 across age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.0 to 5.4 per 1000 PY.

Conclusion: Patients with HS have a significantly higher incidence of both DVT and PE relative to demographically similar patients without HS. This information may support counseling on risk mitigation strategies and safety monitoring during treatment and may provide context for observed (versus expected) thrombotic events in clinical trials for HS.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01913-9.

Related

  1. Renal vein thrombosis with inferior vena cava extension and pulmonary embolism in a patient with acute pyelonephritis: a case report and updated literature review
    Ratna Sutanto, Koesbandono, Marshita Masui +1
    CEN Case ReportsPeer-reviewedLicence not statedFull textGeneral medicinePMC
  2. Genetic Associations with Pulmonary Embolism among Those with a Deep Vein Thrombosis: The INVENT Consortium
    Susana Lozano-Esparza, Gabrielle E. Shakt, Jennifer A. Brody +74
    Journal of Thrombosis and HaemostasisPeer-reviewedLicence not statedGeneral biologyEpidemiology & public healthHAL
  3. Case Report: Pulmonary reperfusion injury with bilateral bronchial cast thrombosis after VA-ECMO-bridged catheter-based reperfusion for cardiac arrest caused by high-risk pulmonary embolism.
    Guanshuai Chen, Fanxiang Chen, Ruoyu Li
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMCCrossref
  4. Patient Selection and Evidence for Intervention in Deep Vein Thrombosis and Pulmonary Embolism
    Cezary Maćkowski, Zbigniew Krasiński, Michał-Goran Stanišić +2
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  5. JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis
    Yuichi Tamura, Kenya Kusunose, Yugo Yamashita +52
    Circulation JournalPeer-reviewedCC BY-NC-NDFull text5 citedCardiovascular medicineJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{garg2026incidence,
  title = {{Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa}},
  author = {Amit Garg and Joslyn Kirby and Theresa Amoloja and J. Morel Symons and Joseph Cordaro and Alex Silberzweig and Andrew Strunk},
  journal = {Dermatology and Therapy},
  year = {2026},
  month = sep,
  doi = {10.1007/s13555-026-01913-9},
  url = {https://doi.org/10.1007/s13555-026-01913-9},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa
AU  - Amit Garg
AU  - Joslyn Kirby
AU  - Theresa Amoloja
AU  - J. Morel Symons
AU  - Joseph Cordaro
AU  - Alex Silberzweig
AU  - Andrew Strunk
PY  - 2026
DA  - 2026/09/01
JO  - Dermatology and Therapy
DO  - 10.1007/s13555-026-01913-9
UR  - https://doi.org/10.1007/s13555-026-01913-9
AB  - Introduction: The risk of thromboembolism in patients with hidradenitis suppurativa (HS) has not been established. This study aimed to estimate the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) among adults with HS and demographic subgroups.  Methods: This retrospective cohort study was conducted between January 1, 2017, and December 31, 2024, using a health insurance claims database (Optum Clinformatics DataMart) in the US. Adults aged ≥ 18 years with an outpatient visit linked to a diagnosis of HS or any other diagnosis (controls) were eligible. Patients with prior diagnosis of either outcome or associated conditions were excluded. The primary outcomes evaluated were new-onset DVT and PE.  Results: Mean (SD) age was 43 (16) years for eligible patients with HS (n = 44,520) and 54 (19) years for control patients (n = 3,792,627). Incidence of DVT was 3.0 (95% CI 2.5–3.4) and 3.5 (95% CI 3.4–3.5) per 1000 person-years (PY) in patients with HS and controls, respectively. Incidence of PE was 2.4 (95% CI 2.0–2.8) and 2.2 (95% CI 2.2–2.3) per 1000 PY in patients with HS and controls, respectively. In demographics-adjusted analyses, standardized incidence ratios for DVT and PE were 1.42 (95% CI 1.23–1.65) and 1.78 (95% CI 1.50–2.10), respectively. Comorbidity-adjusted hazard ratios for DVT and PE were 1.12 (95% CI 0.97–1.31) and 1.35 (95% CI 1.14–1.60), respectively. Incidence of DVT was higher in patients with HS by a factor of 1.5–2.9 for age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.5 to 8.8 per 1000 PY. Incidence of PE was higher in patients with HS by a factor of 1.5–3.2 across age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.0 to 5.4 per 1000 PY.  Conclusion: Patients with HS have a significantly higher incidence of both DVT and PE relative to demographically similar patients without HS. This information may support counseling on risk mitigation strategies and safety monitoring during treatment and may provide context for observed (versus expected) thrombotic events in clinical trials for HS.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01913-9.
SN  - 2193-8210
SN  - 2190-9172
ER  -